HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Engineering a multi-target therapy nanoplatform against tumor growth and metastasis via a novel NSAID-Pt(IV) prodrug.

Abstract
Tumor growth and metastasis are caused by many factors. The complexity means that a multi-target combination therapy strategy should be selected against tumor growth and metastasis. Here, cisplatin (CDDP) and bendazac (Ben) were designed as a novel NSAID-Pt(IV) nanoplatform, which is an effective weapon for combating tumor growth and metastasis.
AuthorsDi Zhang, Jing Nie, Dongbo Wang, Huina Wu, Lei Sun, Xuejian Wang, Jiyong Wu
JournalChemical communications (Cambridge, England) (Chem Commun (Camb)) Vol. 58 Issue 23 Pg. 3803-3806 (Mar 18 2022) ISSN: 1364-548X [Electronic] England
PMID35229844 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Prodrugs
  • Cisplatin
Topics
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cisplatin
  • Humans
  • Neoplasms (drug therapy)
  • Prodrugs (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: